[an error occurred while processing this directive]Hepatitis A-E Slide Set

HEPATITIS_A

 

Properties

A Picornavirus, now classified as a heptovirus, formerly
known as enterovirus 72
Naked icosahedral ssRNA virus
Genome consists of a single +ve stranded RNA with 7478
nucleotides, which codes for 4 proteins ;- VP1 VP2 VP3 VP4
1 serotype only, although there are 4 genotypes
virus can be propagated in primary marmoset cell culture and also in vivo in chimpanzees and marmosets

Electronmicrograph of hepatitis A virus particles.
 

EPIDEMIOLOGY

Hepatitis A occurs endemically in all parts of the world, the exact incidence is hard to estimate because of the high proportion of subclinical infections. At least 1.5 million new cases are reported each year. While the actual incidence in developed countries is decreasing, the infection is almost universal in developing countries. Hepatitis A virus (HAV) is a faecal-oral pathogen and transmission is particularly associated with faecally contaminated food and water. Shellfish is particularly notorious as a vehicle for the spread of HAV. In a recent epidemic in Shanghai following a clam festival, there were over 500,000 cases. Infection is particularly common in conditions of poor sanitation and overcrowding, institutions for the mentally handicapped are particularly vulnerable. Many foodborne outbreaks can be traced to poor hygiene in infected food handlers who were shedding large amounts of virus during the incubation period. The source of the outbreak can often be traced to uncooked food or food that has been handled after cooking. Until recently, about 50% of young adults in the UK had evidence of past infection, but as in the case of other industrialized countries, the incidence is rapidly decreasing so that hepatitis A is rapidly becoming a disease of young adults rather than children in these countries. HAV is frequently acquired from travelers from areas where HAV infection is of a low prevalence to an area where it is hyperendemic.

The incubation period is 3 - 5 weeks (15 - 40 days), with a mean of 28 days. Spread is faecal-oral although bloodborne infection is possible in theory (this was achieved experimentally in volunteers). All age groups are susceptible to HAV. In areas where HAV is hyperendemic, hepatitis A is an childhood infection where the infection is usually subclinical or mild. In developed countries where the overall incidence is decreasing rapidly, the infection is now more commonly seen in adults where the disease is usually more serious.


 
 

PATHOGENESIS

The pathological changes are common to all types of viral hepatitis, with parenchymal cell necrosis and histiocytic periportal inflammation. Rarely in cases of fulminant hepatitis there is massive necrosis. Liver enzymes such as AST and ALT are elevated as a result of release by damaged liver cells. Elevation of these enzymes may often be the only abnormality found in individuals with asymptomatic and anicteric infections who are tested because of known exposure. Serum bilirubin may be elevated, especially in most cases of symptomatic infections and bilirubin may be found in the urine. The leucocyte count is usually normal but sometimes atypical lymphocytes are seen.

Clinical_Features

Following an incubation period of around 4 weeks, at the end of which virus particles are excreted in the faeces, there is an acute onset of non-specific symptoms such as fever, chills, headache, fatigue, malaise, and aches and pains. A few days later, anorexia, N+V and right upper abdominal pain appear, followed by the onset of jaundice with pale stools and dark urine. With the appearance of the jaundice, there is usually a subjective improvement of symptoms. The jaundice deepens for the first few days and then persists for 1 - 2 weeks. Convalescence may be prolonged and complete recovery in adults usually takes place within a few months. In children the infection is commonly asymptomatic or the prodromal phase mild or absent. The mortality rate is very low for hepatitis A and no carrier state exists.

Complications of hepatitis A include prolonged cholestatic jaundice which responds to corticosteroid therapy, and relapsing disease which occurs in 6 to 10% of patients and lasts 16 to 40 weeks. Relapsing disease appears to be immunologically mediated and must not be treated by corticosteriods. Extrahepatic complications include a rash and arthropathy.

LABORATORY_DIAGNOSIS

1. Detection of the virus or antigen ;- The virus can be detected in the faeces up to 2 weeks before the appearance of the jaundice and up to 2 weeks afterwards. However by the time that jaundice appears, viral titres in the faeces are already at a low titre and so in practice EM if the stools is rarely of diagnostic value. Hepatitis A virus can also be detected in the serum, saliva, urine and semen although transmission is unlikely to take place via these routes. There had been anecdotal reports of hepatitis A transmitted through blood transfusions.

2. Serology ;- This is the method of choice for the diagnosis of acute hepatitis A. A variety of ELISAs and RIAs are available. The detection of specific IgM is diagnostic of recent infection. (IgM may be found 45 - 60 days after the onset of symptoms). Serum IgG is used in determining the immune status of the individual before the prescription of immunoglobulin for foreign travel.
 


 
 
 

PREVENTION_AND_CONTROL_OF_HEPATITIS_A

The control of infection is difficult as the height of faecal excretion occurs during the late incubation period and the prodromal phase. Isolation of cases is not strictly necessary as a control measure. The spread of HAV can be reduced by simple hygienic measures and the sanitary disposal of excreta. HNIG containing at least 100 i.u./ml of anti-HAV given before exposure to the virus or early during the incubation period will prevent or attenuate a clinical illness. Immunoglobulin does not always prevent infection and the excretion of HAV. HNIG is used most commonly for close personal contacts of patients with hepatitis A and has also been successfully used in controlling outbreaks in institutions. However since maximal virus excretion has already passed by the time clinical symptoms appear, HNIG is probably of little value in preventing infection in a household although it may in theory attenuate the course of the disease in contacts. The RVL policy is to discourage the prescribing of HNIG in the case of family contacts. However consideration should be given to protect people at risk in an institution. There HNIG would only be given to adults where the consequence of infection is much more severe than children. The doses used are as follows ;-

Under 10 years 250 mg
10 years and over 500 mg

HNIG is used for prophylaxis for travelers to areas with a high endemicity. In practice, hepatitis A occurs 100 times more frequently in travellers than typhoid fever. The protection is valid for 6 months, after which the administration should be repeated ;-

Period Abroad     Age     Dose

0 - 2 months     < 10     125 mg
                >= 10     250 mg

3 - 5 months     < 10     250 mg
                >= 10     500 mg

Various live attenuated and killed vaccines that have been prepared from viral cell cultures are being evaluated at present. These vaccines would be most useful in protecting travelers and susceptible people working in institutions.

"HAVRIX" (SmithKline Beecham) is a formaldehyde-inactivated vaccine prepared from HAV HM 175 grown in human diploid cells. It is available in prefilled syringes containing a turbid, white suspension. Each 1 ml dose contains no less than 720 ELISA units of hepatitis A viral protein absorbed on aluminium hydroxide adjuvant. The vaccine is recommended for those at increased risk of infection. This includes those traveling to, or living in, medium or high endemicity ares. Other high risk groups include recent close contacts of infected individuals and potential contacts of cases such as childcare or healthcare workers. In the event of case contact, HBIG should be given simultaneously with HAVRIX in different sites. "HAVRIX" is given im and the regimen consists of 2 doses of 1ml of vaccine spaced 2 weeks to 1 month apart and provides anti- HAV antibodies for at least 1 year. In order to obtain more persistent immunity of up to 10 years, a 1 ml booster dose is recommended between 6 to 12 months following the initial dose.

"HAVRIX" should not be given to those with severe febrile infections. In haemodialysis patients and in immunocompromized subjects, adequate antibody titres may not be obtained after the primary immunization course and such patients may therefore require administration of additional doses of vaccine. "HAVRIX" can be given with recombinant Hepatitis B vaccine and interference is unlikely to occur with other inactivated or live vaccines. Although the risks in pregnancy are probably negligible, the vaccine is not recommended in pregnancy unless there is a definite risk of hepatitis A. Adverse reactions are usually mild and confined to the first few days after vaccination. The most common complaints are soreness, erythema and induration at the injection site.
 

[an error occurred while processing this directive]

CDC hepatitis branch; "Epidemiology and Prevention of Hepatitis A-E: An Overview"
 

Hepatitis A-E Slide Set